ESR1 and breast carcinoma: The ability of NP-R and NP to modulate NGB levels has been tested on two ERα-positive breast cancer cell lines (i.e., MCF-7 and T47D), and one ERα-negative breast cancer cell line (i.e., MDA-MB-231) [17].